For patients with psoriasis receiving biologic therapy, residual inflammation (RI), defined as increased inflammatory markers in blood, characterized by high-sensitivity C-reactive protein, despite ...

New research shows that in patients with psoriasis, even though their skin responds well to treatment with biologics, ...

Discover a study in which researchers examined three international cohorts of patients with moderate-to-severe psoriasis ...

Bimekizumab use for 4 years among patients with plaque psoriasis is associated with sustained efficacy outcomes and no new safety signals.

Skin symptoms may clear with biologics in psoriasis, but hidden internal inflammation often persists, contributing to major ...

Starjemza (ustekinumab-hmny) was approved by the FDA this week as a biosimilar to Stelara. 2 A pair of clinical trials ...

May 27, 2025 — Researchers have found that central body fat, especially around the abdomen, is more strongly linked to psoriasis risk than total body fat, particularly in women. This link ...

Residual inflammation persisted among patients with psoriasis despite optimal disease response to biologic therapies, putting ...

A new study highlights a significant medical concern for individuals suffering from psoriasis, revealing that even when skin ...

Certain biologic therapies, such as ustekinumab, significantly effect hematological and lipid parameters in patients with psoriasis.

THURSDAY, May 29, 2025 (HealthDay News) — Belly flab appears to be a stronger warning sign for psoriasis than fat located ...